Anavex Life Sciences Corp (AVXL)

[falconer66a]

Will Reconsiderations of Blarcamesine and Anavex Appear?

Anavex made this announcement:

Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ being held May 20th, 2024 at 10:00am ET at NASDAQ World Headquarters New York City.

It will be interesting to notice in his conversation on Monday if Missling mentions the FDA’s new approach to the ADL co-primary endpoint, which has now been abandoned.

As Smiggins importantly mentioned in his post (post# 459312):

...the ADL co-primary endpoint, the multiplicity issue has disappeared. So, going forward, we see that the small, 508 n Anavex AD 2b/3 is not squeaking by on p values; instead, it's a convincing win with a cognition p value of .0226 blowing past the .05 gatekeeping figure.

Then, how will this FDA change affect the eventual appearance of the promised peer-reviewed journal article on the blarcamesine clinical trials results for Alzheimer’s?

Does it begin to seem that Anavex has significant new announcements that will be appearing soon? Will either of these announcements, when more fully described and understood by potential AVXL investors, prompt reconsiderations of blarcamesine on The Street?

If I had funds tied up in paying the borrowing costs of holding an AVXL short position I’d be doing some heavy thinking right now.